303 related articles for article (PubMed ID: 19723891)
1. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
van Rhee F; Szmania SM; Dillon M; van Abbema AM; Li X; Stone MK; Garg TK; Shi J; Moreno-Bost AM; Yun R; Balasa B; Ganguly B; Chao D; Rice AG; Zhan F; Shaughnessy JD; Barlogie B; Yaccoby S; Afar DE
Mol Cancer Ther; 2009 Sep; 8(9):2616-24. PubMed ID: 19723891
[TBL] [Abstract][Full Text] [Related]
2. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Hsi ED; Steinle R; Balasa B; Szmania S; Draksharapu A; Shum BP; Huseni M; Powers D; Nanisetti A; Zhang Y; Rice AG; van Abbema A; Wong M; Liu G; Zhan F; Dillon M; Chen S; Rhodes S; Fuh F; Tsurushita N; Kumar S; Vexler V; Shaughnessy JD; Barlogie B; van Rhee F; Hussein M; Afar DE; Williams MB
Clin Cancer Res; 2008 May; 14(9):2775-84. PubMed ID: 18451245
[TBL] [Abstract][Full Text] [Related]
3. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
[TBL] [Abstract][Full Text] [Related]
4. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Tai YT; Dillon M; Song W; Leiba M; Li XF; Burger P; Lee AI; Podar K; Hideshima T; Rice AG; van Abbema A; Jesaitis L; Caras I; Law D; Weller E; Xie W; Richardson P; Munshi NC; Mathiot C; Avet-Loiseau H; Afar DE; Anderson KC
Blood; 2008 Aug; 112(4):1329-37. PubMed ID: 17906076
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
Jakubowiak AJ; Benson DM; Bensinger W; Siegel DS; Zimmerman TM; Mohrbacher A; Richardson PG; Afar DE; Singhal AK; Anderson KC
J Clin Oncol; 2012 Jun; 30(16):1960-5. PubMed ID: 22291084
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
7. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
Stein R; Smith MR; Chen S; Zalath M; Goldenberg DM
Clin Cancer Res; 2009 Apr; 15(8):2808-17. PubMed ID: 19351768
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
[TBL] [Abstract][Full Text] [Related]
9. Profile of elotuzumab and its potential in the treatment of multiple myeloma.
Liu YC; Szmania S; van Rhee F
Blood Lymphat Cancer; 2014 Jun; 2014(4):15-27. PubMed ID: 26005365
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
11. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
[TBL] [Abstract][Full Text] [Related]
12. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
Collins SM; Bakan CE; Swartzel GD; Hofmeister CC; Efebera YA; Kwon H; Starling GC; Ciarlariello D; Bhaskar S; Briercheck EL; Hughes T; Yu J; Rice A; Benson DM
Cancer Immunol Immunother; 2013 Dec; 62(12):1841-9. PubMed ID: 24162108
[TBL] [Abstract][Full Text] [Related]
13. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Mai EK; Goldschmid H; Miah K; Bertsch U; Besemer B; Hänel M; Krzykalla J; Fenk R; Schlenzka J; Munder M; Dürig J; Blau IW; Huhn S; Hose D; Jauch A; Kunz C; Mann C; Weinhold N; Scheid C; Schroers R; von Metzler I; Schieferdecker A; Thomalla J; Reimer P; Mahlberg R; Graeven U; Kremers S; Martens UM; Kunz C; Hensel M; Benner A; Seidel-Glätzer A; Weisel KC; Raab MS; Salwender HJ;
Lancet Haematol; 2024 Feb; 11(2):e101-e113. PubMed ID: 38302221
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
15. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS
Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433
[TBL] [Abstract][Full Text] [Related]
16. In vivo anti-tumor efficacy of afucosylated anti-CS1 monoclonal antibody produced in glycoengineered Pichia pastoris.
Gomathinayagam S; Laface D; Houston-Cummings NR; Mangadu R; Moore R; Shandil I; Sharkey N; Li H; Stadheim TA; Zha D
J Biotechnol; 2015 Aug; 208():13-21. PubMed ID: 26015261
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
Wang X; Feng X; Wang J; Shao N; Ji C; Ma D; Henter JI; Fadeel B; Zheng C
Anticancer Drugs; 2014 Mar; 25(3):282-8. PubMed ID: 24300915
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic antibodies for multiple myeloma.
Ishida T
Jpn J Clin Oncol; 2018 Nov; 48(11):957-963. PubMed ID: 30329116
[TBL] [Abstract][Full Text] [Related]
19. Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.
Panaampon J; Kariya R; Okada S
Cancer Immunol Immunother; 2022 Oct; 71(10):2497-2509. PubMed ID: 35262781
[TBL] [Abstract][Full Text] [Related]
20. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A; Sonneveld P
Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]